Document:

Severance Agreement

 Exhibit 10.2 
 SEVERANCE AGREEMENT 
 AGREEMENT, made and entered into as of January 22, 2008, by and between
TUTOGEN MEDICAL, INC., a Florida corporation (the “Company”), and L. Robert Johnson, Jr. (the “Employee”). 
 WHEREAS,
the Company desires to provide the Employee with severance payments in the event there is a sale of the Company (a “Transaction”—which is defined in Section 10(c) below), and Employee is terminated for cause or resigns for good
reason within 24 months of such Transaction, in consideration of Employee’s release of claims and certain agreements by Employee with respect to non-competition, non-solicitation, and non-disparagement, among other things. 
 NOW THEREFORE, the parties agree as follows: 
 1. Severance Protection. (a) If a Transaction occurs and if, before the second anniversary of the date on which the Transaction is consummated, the Company or any successor entity (the “Employer”) terminates
Employee’s employment without “Cause” or such employment is terminated by the Employee for “Good Reason” (as both such terms are defined below), then, within ten days following such termination of employment (a
“Severance Termination”), the Employee will be entitled to receive from the Employer an amount equal to the difference between: (a) 12 months (the “Severance Period”) of the Employee’s then current salary, and
(b) any severance Employee has become entitled to receive as a result of such Transaction or the termination of the Employee’s employment pursuant to that certain letter agreement, dated December 28, 2005, by and between the Company
and Employee (the “Letter Agreement”), in equal biweekly installments during the 24 month period subsequent to such termination, payable in accordance with the Employer’s normal payroll practices. If after 24 months of such
transaction the Employee is terminated without cause or due to a change of control, the Employee will be entitled to 6 months of salary in accordance with the Letter Agreement. 
 (b) In the event of a Severance Termination, the Company agrees to reimburse Employee for the Consolidated Omnibus Reconciliation Act (“COBRA”)
continuation premium to continue the Employee’s current health/dental insurance coverage through the earlier of: (i) the end of the maximum period subsequent to such termination provided for under COBRA, (ii) the end of the Severance
Period, (iii) such date that the Employee becomes eligible for enrollment for other health/dental care coverage, as the case may be, under another group health/dental plan prior to the end of this period. To be eligible for such reimbursement
of COBRA continuation premium payments by the Company, the Employee must elect COBRA continuation coverage when contacted by the Company or the Company’s provider of COBRA services. If COBRA continuation coverage is elected by Employee, he or
she must pay the monthly premiums and provide Company with evidence of payment for reimbursement. After the end of the Severance Period, if the Employee is still eligible under COBRA and wishes to maintain COBRA continuation coverage beyond such
date, the Employee will be responsible for all COBRA continuation premium payments after such date. 
  

 -i- 

 (c) In the event of a Severance Termination, the Company agrees to pay the Employee for any accrued,
unused paid time off leave time, to be paid to Employee 10 days after termination of employment. The Employee will not accrue any additional paid time off leave after such date. 
 (d) In the event of a Severance Termination, the Employee will be allowed to continue vesting in any unvested stock/option grants made by the Company, or
any successor, to Employee until the end of the Severance Period. Any and all other remaining unvested stock/option grants as of the end of the Severance Period, will be forfeited. Any vested options must be exercised within 90 days of the end of
the Severance Period. 
 2. Effect of Other Agreements. If the Employee becomes entitled to receive severance payments under this
Agreement, such payments will be in lieu of and not in addition to the benefits, severance payments or other payments to which Employee may otherwise have been entitled under any prior change of control, severance or other agreement between the
Company and Employee. 
 3. Release of Claims. Notwithstanding anything to the contrary contained herein, the Employer shall have the
right to condition Employee’s right to receive severance payments and benefits under Section 1 of this Agreement upon the execution and delivery by the Employee (or Employee’s beneficiary) of a general release in favor of Company,
Employer and its successors and affiliates, and their officers, directors and employees, in such form as the Employer may specify. Any payment or benefit that is so conditioned may be deferred until the expiration of the seven day revocation period
prescribed by the Age Discrimination in Employment Act of 1967, as amended (or any similar revocation period then in effect). 
 4.
Non-Competition. 
 (a) The Employee acknowledges, recognizes and understands that, in connection with the Employee’s employment
with the Employer, the Employee has and will have access to certain proprietary, sensitive and confidential information of the Employer including but not limited to: the identity of the Employer’s clients, prospective clients, and other client
information; the existence of negotiations with prospective clients of the Employer; marketing data and plans; financial information and financial data not publicly disclosed; all drawings, records, sketches, and models; trade secrets and trade
secrets relating to services of the Employer; and, products sold or being developed by the Employer (“Confidential Information”). Employee also acknowledges, recognizes and understands that the Employer owns or has access to various types
of intellectual property that are protected or may be protected by copyright, trademark, patent, trade secret, or other laws. The types of intellectual property that are considered proprietary to the Employer and that must be protected include but
are not limited to: patent applications; trademarks; programs; source and relocatable code for all programs; engineering, research, and technical documents; unpublished product specifications; products sold or under development; and, information
belonging to other companies that is provided to the Employer under confidentiality agreements (“Intellectual Property”). 
 (b)
Employee recognizes that the Employer possesses several valuable and legitimate business interests such as Confidential Information and Intellectual Property, 

  

 -ii- 

 
substantial relationships with current or prospective customers, clients or vendors, and customer, client or vendor goodwill associated with the Employer
business. In recognition of these interests, and the Employee’s exposure to these interests, in the event of the termination of the Employee’s employment with the Employer, the Employee agrees that for a period of two (2) years
following the effective date of the termination (the “Restricted Period”), the Employee will not be employed, either as director, employee, owner, partner, contractor or consultant, by any entity which engages in the business of
manufacturing, distributing, processing, procuring or recovering products made from allograft or xenograft tissue in the United States (each, a “Competing Organization”). The Competing Organizations that Employee agrees not to become
employed by during the Restricted Period include, without limitation: Axogen, Inc., Pegasus Biologics, Inc., Osiris Therapeutics, Inc., Southeast Tissue Alliance, Inc. (University of Florida Tissue Bank), Musculoskeletal Transplant Foundation;
CryoLife; LifeCell; Allosource; Tissue Banks International; Osteotech, Inc.; LifeLink Tissue Bank; Life Net; Community Tissue Services; American Red Cross; BioGenetics; and, Cryogenic. The Employee also agrees that during the Restricted Period he
will not participate in, assist with or in any way become associated with or employed by any new start up venture that is or will be engaged in the business of a Competing Organization, or which the Employer reasonably designates as a Competing
Organization. Notwithstanding the foregoing, nothing herein shall prevent Employee owning up to 1% of the capital stock of a Competing Business. 
 (c) The Employee acknowledges that this restrictive covenant is reasonably necessary to protect the Employer’ legitimate business interests, which are represented by, among other things, the substantial relationships between the
Employer and its licensees and tissue sources, as well as the goodwill established by the Employer with licensees and tissue sources in the United States and other countries where the Employer’s tissues are distributed over a protracted period,
specialized training, and other legitimate business reasons. 
 (d) The Employee recognizes that the Employer would not sign this Agreement
without the inclusion of this covenant, and the Employee confirms the sufficiency of the consideration received by the Employee, in the form of continued employment by the Employer and the payments described in Section 1 hereof, in accepting
this covenant as a material term of this Agreement. The provisions of this Section 5 shall survive the termination of Employee’s employment with the Employer and the termination of this Agreement. 
 5. Non-Solicitation. 
 The
Employee agrees during the Restricted Period, not to: (a) solicit any employee of the Employer, or any subsidiary or affiliate of the Employer, or otherwise induce or attempt to induce any employee of the Employer to leave the employment of the
Employer; or (b) directly or indirectly attempt to solicit any client, customer or supplier of the Employer, or any client, customer or supplier of any subsidiary or affiliate of the Employer, or directly or indirectly interfere with the
Employer’s relationship, or any subsidiary’s or affiliate’s relationship, with any of its clients, customers or suppliers. The provisions of this Section 6 shall survive the termination of Employee’s employment with the
Employer and the termination of this Agreement. 
  

 -iii- 

 6. Remedies for Breach of Non-Competition and Non-Solicitation Provisions. 
 It is understood and agreed by the Parties that the Employer shall be entitled, upon application to a court of competent jurisdiction, to obtain
injunctive relief to enforce the provisions of Sections 5 and 6, which injunctive relief shall be in addition to any other rights or remedies available to the Employer. If such a violation is deemed by such court to have occurred, the Employee shall
be responsible for the payment of reasonable attorneys’ fees and other costs and expenses incurred by the Employer in enforcing the covenants contained in Sections 5 and 6, whether incurred at the trial level or in any appellate proceeding and
conversely, if such court determines that a violation did not occur, then the Employer shall be responsible for the payment of reasonably attorney’s fees and other costs and expenses incurred by Employee in defending such action, whether
incurred at the trial level or in any appellate proceeding. 
 7. Non-Disparagement. 
 While employed or engaged as a consultant by the Employer or any affiliate of the Employer and, provided the Employer has complied with its obligations
hereunder, after the Employee’s employment terminates for whatever reason the Employee agrees not to disparage, denigrate, or comment negatively upon, either orally or in writing, the Employer, or any of its affiliates, officers, or directors,
to or in the presence of any person or entity. After the Employee’s employment terminates for whatever reason, the Company agrees that its officers, directors, and key employees will not disparage, denigrate, or comment negatively upon, either
orally or in writing, the Employee. 
 8. Definitions. For purpose of this Agreement, the following terms shall have the meanings set
forth below: 
 (a) “Cause” means: 
 (i) willful failure or refusal by the Employee to substantially perform the material duties of his or her employment, and failure to cure such failure or refusal within 10 days of delivery to Employee of written
notice thereof by the Company; 
 (ii) conviction of the Employee for commission of a felony, including without limitation, fraud,
embezzlement or theft, whether or not such felony was committed in connection with the Employer’s business; 
 (iii) use by Employee of
alcohol or illegal drugs materially interfering with the performance of Employee’s duties and obligations under this Agreement, or Employee being under the influence of illegal drugs or repeatedly under the influence of alcohol at a facility of
Employer; 
 (iv) willful or grossly negligent misconduct which results or could reasonably be expected to result in material damage to the
business or assets of the Employer; 
 (v) violation by Employee of any of the covenants in Sections 4, 5 or 7 of this Agreement; or

  

 -iv- 

 (vi) willful breach of this Agreement or any material employment policy of the Employer, and failure to
cure such breach within 10 days of delivery to Employee of written notice thereof by the Company. 
 (b) “Good Reason” means:
(a) a diminution of duties, responsibilities and compensation that are materially inconsistent with Employee’s current position as of the date hereof; provided, however, that: (i) a diminution in position, title or
working conditions, or (ii) the Employer’s failure to continue the Employee’s existing authority, duties, reporting relationship and/or responsibilities resulting from the direct or indirect control of the Employer by another company,
any sale or transfer of equity, property or other assets of the Employer or any of its Subsidiaries, and any diminution of the business of the Employer or any of its Subsidiaries, shall not constitute “Good Reason”, or (b) relocation
by more than 50 miles of the Employee’s principal place of employment. 
 (c) “Transaction” means (1) the completion of
the sale or other disposition of all or substantially all of the assets of the Company to a party unaffiliated with the Company, or (2) the completion of a merger or other transaction relating to the Company if neither the Company nor its
stockholders immediately prior to such merger or other transaction hold, directly or indirectly, more than 50% of the voting power of the surviving corporation or other entity resulting from such merger or other transaction. 
 9. General Provisions. 
 (a) Nothing
in this Agreement is intended to create a contract of employment between Employee and the Company or any of its subsidiaries, or to interfere in any way with the right of the Company or any of its subsidiaries to terminate Employee’s employment
at any time. 
 (b) All payments made pursuant to this Agreement will be subject to applicable withholding requirements. 
 (c) If, at the time of the Employee’s termination of employment, the Employee is a “specified employee” within the meaning of Treasury
Regulation Section 1.409A-1(a)(i), then, notwithstanding anything to the contrary contained herein, payments and benefits to which the Employee will be entitled by reason of such termination of employment shall be delayed for six months
following the Employee’s termination of employment if and to the limited extent necessary in order to satisfy the requirements of Section 409A(a)(2)(B) of the Internal Revenue Code of 1986. For the avoidance of doubt, payments and benefits
will not be delayed if and to the extent such payments and benefits do not constitute deferred compensation under Section 409A of the Code, including, without limitation, by reason of the exceptions described in Section 1.409A-1(b)(9). Any
payments that are delayed pursuant to this subparagraph will be made in a single lump sum at the expiration of the required delay period (but not later than six months after termination of employment). 
 (d) This Agreement will be governed by and construed in accordance with the laws of the State of Florida without regard to its conflict of laws
provisions. 
  

 -v- 

 (e) No amendment or modification of this Agreement may be made except by a written instrument signed by
the Company and Employee. 
 (f) This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but
all of which taken together will constitute one and the same agreement. 
 (g) This Agreement constitutes the entire agreement between the
parties hereto relating to the matters encompassed hereby and supersedes any prior oral or written agreements relating thereto; provided, however, that this Agreement does not modify or supersede any agreements between the Company and Employee
regarding confidentiality or assignment of inventions. 
  

 -vi- 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.

  

							
		 		 	TUTOGEN MEDICAL, INC.
				
		 		 	By:	 	 /s/ Guy L. Mayer

		 		 	Name:	 	Guy L. Mayer
		 		 	Title:	 	Chief Executive Officer
	Accepted and Agreed on January 22, 2008 by:	 		 	
				
	 /s/ L. Robert Johnston, Jr.
	 		 		 	
	L. Robert Johnson, Jr.	 		 		 	

  

 -vii-Bonus conversion program (2008 plan year)

 Exhibit 10.15 
 Bonus Conversion Program 
 Program Year 2008 
 Summary of Program Terms 
 Program Objectives 
  

	•	 	 To increase the opportunity for employee ownership of Stericycle stock 

  

	•	 	 To provide an alternative means of deferring the tax obligation on incentive compensation 

 Program Overview 
 The Bonus Conversion Program
provides you with an opportunity to defer current taxation into the future and to increase your ownership of Stericycle stock. This Program allows you to receive a vested Stericycle non-qualified stock option in lieu of all or a portion of any
annual, quarterly or monthly cash bonus that Stericycle otherwise would pay you. If you elect to participate for the 2008 Program Year, you will receive a vested option during the first quarter of 2009 to purchase $3.00 or more worth of Stericycle
stock for every $1 of your annual bonus, quarterly bonuses or monthly bonuses for 2008 that you elected to forego. The number of option shares will be equal to (a) 3 times the amount that you elected to forego divided by (b) the average
closing price of Stericycle stock during 2008. The exercise price per share of the option will be the closing price of the stock on the date of the option grant. For example, if under this Program you elect to forego $10,000 of your annual bonus for
2008, you will receive a vested option to purchase, at the option exercise price, a number of shares equal to $30,000 divided by the average closing price of Stericycle stock during 2008 (or, if lower, the closing price on the date of the option
grant). 
 The Bonus Conversion Program provides participants with an excellent opportunity to accumulate wealth if Stericycle stock performs
well. A stock investment includes a potential for significant gain as well as an investment risk. The program is designed to provide a $3.00-for-$1 or greater replacement ratio or premium for risk because if you participate you will be trading
certain cash for uncertain investment gain. With the $3.00-for-$1 or greater replacement ratio, your potential for gain depends on whether Stericycle stock performs well. However, your risk is that Stericycle stock may not appreciate and you may not
recover the amount of your cash bonus given up or match the earnings you could have received under an alternative investment. 
 Enrollment

 THE ENCLOSED ELECTION FORM MUST BE COMPLETED AND RETURNED AS INDICATED ON THE FORM. THIS FORM MUST BE COMPLETED AND RETURNED EVEN IF
YOU ELECT NOT TO PARTICIPATE. YOUR PARTICIPATION IN THE PROGRAM IS NOT A STERICYCLE PROMISE THAT YOU WILL RECEIVE A BONUS OF ANY PARTICULAR AMOUNT OR ANY BONUS AT ALL. 

 Program Design 
  

	•	 	 Participants may elect to convert up to 100% of their annual, quarterly or monthly cash bonuses for 2008 (if any) (minimum of $1,000 in the aggregate) into a
Stericycle non-qualified stock option 

  

	•	 	 Eligibility: Grade level S11 and above as approved by Board of Directors 

  

	•	 	 Replacement ratio, or premium for risk, is $3.00 or more for options to purchase Stericycle stock for every $1 of cash bonus foregone. 

 

	•	 	 The number of option shares will be equal to (a) 3 times the amount that a participant elected to forego divided by (b) the average closing price of
Stericycle stock during 2008 (or, if lower, the closing price on the date of the option grant). The exercise price per share of the option will be the closing price of Stericycle stock on the date of the option grant. 

 

	•	 	 In the case of quarterly or monthly bonuses, the percentage that a participant elects to convert will apply to each of the participant’s quarterly or monthly
bonuses for 2008. 

  

	•	 	 Participants forego all or a portion of their cash bonuses (before any withholding that would have been taken out) in order to receive stock options. Generally, a
participant will be taxed at ordinary income rates on the option gain upon exercise of the stock option. Upon sale of the shares, any additional gain or loss will be taxed as short-term or long-term capital gain or loss depending on the holding
period of the stock for tax law purposes. 

  

	•	 	 An election to participate in this Program must be made by the election deadline to avoid constructive receipt and securities law restrictions. An election is
irrevocable and cannot be changed by the participant after the election deadline. New employees who start after January 31, 2008 will not be eligible to participate in the Bonus Conversion Program for 2008. 

  

	•	 	 Participants vest in the stock options immediately. 

  

	•	 	 Option term: 10 years – participants have 10 years from date of grant to exercise options. 

  

	•	 	 In the event of death, disability, resignation, retirement, or other termination of employment (other than termination for cause), the stock option remains
exercisable until the end of the 10-year option term. 

 Any stock options you elect to receive will be issued under any
available Stericycle Stock Option Plan and the terms of that Plan and the related Option Agreement will apply to your stock option. 
  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]